296,050 Shares in CeriBell (NASDAQ:CBLL) Bought by Lord Abbett & CO. LLC

Lord Abbett & CO. LLC purchased a new stake in CeriBell (NASDAQ:CBLL - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 296,050 shares of the company's stock, valued at approximately $7,662,000. Lord Abbett & CO. LLC owned about 0.83% of CeriBell as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of CBLL. Rhumbline Advisers bought a new position in CeriBell in the 4th quarter valued at approximately $320,000. Bank of New York Mellon Corp acquired a new stake in shares of CeriBell during the 4th quarter valued at $628,000. Charles Schwab Investment Management Inc. bought a new stake in CeriBell during the 4th quarter worth $2,500,000. PNC Financial Services Group Inc. acquired a new position in CeriBell in the 4th quarter worth about $47,000. Finally, Vanguard Group Inc. bought a new position in CeriBell in the fourth quarter valued at about $18,015,000.

Insider Transactions at CeriBell

In other CeriBell news, CEO Xingjuan Chao sold 5,700 shares of the stock in a transaction that occurred on Thursday, April 17th. The stock was sold at an average price of $15.02, for a total value of $85,614.00. Following the transaction, the chief executive officer now owns 746,451 shares in the company, valued at approximately $11,211,694.02. This represents a 0.76 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold 24,700 shares of company stock valued at $372,434 in the last 90 days.

CeriBell Stock Performance

Shares of NASDAQ:CBLL traded up $0.04 during trading on Friday, reaching $16.32. The stock had a trading volume of 208,040 shares, compared to its average volume of 270,817. CeriBell has a 52 week low of $10.01 and a 52 week high of $32.75. The business's fifty day moving average is $18.85.

CeriBell (NASDAQ:CBLL - Get Free Report) last issued its quarterly earnings results on Tuesday, February 25th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.08). The business had revenue of $18.53 million during the quarter, compared to analysts' expectations of $17.55 million. As a group, sell-side analysts anticipate that CeriBell will post -2.46 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts have recently issued reports on the company. LADENBURG THALM/SH SH began coverage on CeriBell in a research note on Friday, April 4th. They issued a "buy" rating and a $32.00 price objective for the company. Canaccord Genuity Group reiterated a "buy" rating and set a $33.00 price target on shares of CeriBell in a report on Wednesday, February 26th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of "Buy" and a consensus price target of $32.50.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.